Hackensack University Medical Center
- Type
- Teaching hospital
- Where
- Hackensack, NJ
- Medicare CCN
- 310001
- Received
- $16,104,044 in 1,835 records, 2023 ($764,325 general, $15,339,719 research)
- Source
- CMS Open Payments search ↗
On this site
- Patent assignee: Hackensack University Medical Center Fuzzy (name and state)
- Trademark owner: Hackensack University Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 152 | $764,325 |
| 2023 | Research payment | 1,683 | $15,339,719 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,683 | $15,339,719 |
| Grant | 5 | $339,672 |
| Long term medical supply or device loan | 101 | $170,369 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 22 | $146,900 |
| Debt forgiveness | 6 | $81,525 |
| Space rental or facility fees (teaching hospital only) | 12 | $24,862 |
| Education | 2 | $500 |
| Food and Beverage | 3 | $445 |
| Charitable Contribution | 1 | $50 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Gilead Sciences, Inc. | $300,672 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $134,393 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $120,472 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $73,429 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $63,212 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo- and Active-ComparatorControlled Clinical study of Adjuvant V940 mRNA-4157 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $56,834 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study# A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizuma | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $46,139 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Open-Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $31,096 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $30,019 | Research payment | In-kind items and services | ZOLINZA Drug, ONCOLOGY | A Phase I,II study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in relapsed and,or refractory multiple my | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $28,472 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $27,240 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $24,506 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants wi | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $21,090 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $18,252 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $17,120 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $15,507 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $15,002 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Philips North America LLC | $15,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | Optimization of New MR Cardiac Imaging Techniques | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $14,236 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $12,747 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $11,157 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $11,084 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $10,836 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $8,880 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $8,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,252 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $5,902 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $5,273 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,791 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,120 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,065 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurren | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $3,024 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $2,629 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,116 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chem | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,488 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2023 |
| 2023-12-31 | Stryker Corporation | $1,272 | Long term medical supply or device loan | In-kind items and services | STRYKER F1 Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $1,272 | Long term medical supply or device loan | In-kind items and services | STRYKER F1 Device, SURGICAL | 2023 | |
| 2023-12-31 | ABBVIE INC. | $1,000 | Research payment | In-kind items and services | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-31 | ABBVIE INC. | $1,000 | Research payment | In-kind items and services | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $762 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $742 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Sche | 2023 |
| 2023-12-31 | Philips North America LLC | $600 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | Optimization of New MR Cardiac Imaging Techniques | 2023 |
| 2023-12-31 | Philips North America LLC | $600 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | Optimization of New MR Cardiac Imaging Techniques | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $350 | Research payment | In-kind items and services | A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy i | 2023 | |
| 2023-12-31 | Acerta Pharma LLC | $293 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2023 |
| 2023-12-31 | Medline Industries LP | $222 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $95 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2023 |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $78 | Long term medical supply or device loan | In-kind items and services | SECURE CONNECT Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Linvatec Corporation | $27 | Long term medical supply or device loan | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2023 | |
| 2023-12-31 | Sumitomo Pharma America, Inc. | $24 | Research payment | Cash or cash equivalent | A Phase 1 Study of DSP-0390 in Patients with Recurrent High-grade Glioma | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $14 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus | 2023 |
| 2023-12-31 | Stryker Corporation | $1 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced,Metastatic Adenoca | 2023 |
| 2023-12-29 | Olympus America Inc. | $24,310 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-12-28 | Pharmacyclics LLC, an AbbVie Company | $789 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD | 2023 |
| 2023-12-28 | ABBVIE INC. | $95 | Research payment | Cash or cash equivalent | A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants | 2023 | |
| 2023-12-26 | ABBVIE INC. | $11,775 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-22 | ABIOMED | $16,900 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Use of Impella ECP8482 in Patients Undergoing an Elective or Urgent High-Risk PCI | 2023 |
| 2023-12-22 | SANOFI US SERVICES INC. | $11,866 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-22 | Genmab A/S | $11,859 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory | 2023 |
| 2023-12-22 | PFIZER INC. | $5,056 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2023 |
| 2023-12-22 | Incyte Corporation | $351 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | 2023 | |
| 2023-12-22 | Incyte Corporation | $284 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | 2023 | |
| 2023-12-22 | SANOFI US SERVICES INC. | $261 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-22 | Incyte Corporation | $126 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | 2023 | |
| 2023-12-22 | Incyte Corporation | $56 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | 2023 | |
| 2023-12-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $15,810 | Research payment | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MO | 2023 |
| 2023-12-21 | Sumitomo Pharma America, Inc. | $11,596 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and wit | 2023 | |
| 2023-12-21 | Genentech, Inc. | $9,600 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2023 |
| 2023-12-21 | ABBVIE INC. | $5,320 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menst | 2023 |
| 2023-12-21 | Insulet Corporation | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-12-20 | Kite Pharma, Inc. | $29,441 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH P | 2023 |
| 2023-12-20 | ABBVIE INC. | $10,731 | Research payment | Cash or cash equivalent | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult P | 2023 | |
| 2023-12-20 | BeiGene USA, Inc. | $4,899 | Research payment | Cash or cash equivalent | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumo | 2023 | |
| 2023-12-20 | Genmab A/S | $4,772 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $4,772 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $4,680 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $4,680 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $4,680 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $3,942 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | BeiGene USA, Inc. | $2,915 | Research payment | Cash or cash equivalent | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumo | 2023 | |
| 2023-12-20 | BeiGene USA, Inc. | $470 | Research payment | Cash or cash equivalent | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumo | 2023 | |
| 2023-12-20 | Otsuka Pharmaceutical Co., Ltd. | $265 | Research payment | Cash or cash equivalent | A MULTI-PHASE, DOSE-ESCALATION FOLLOWED BY AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY OF ORAL ASTX030 (CEDAZURIDINE AND | 2023 | |
| 2023-12-19 | ABIOMED | $1,200 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Use if the Impella BTR in Patiennts with Heart Failure | 2023 |
| 2023-12-19 | Servier BioInnovation | $490 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAG | 2023 |
| 2023-12-18 | Merck Sharp & Dohme LLC | $18,271 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $10,125 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-18 | GENZYME CORPORATION | $8,191 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 | |
| 2023-12-18 | Genentech, Inc. | $2,082 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $361 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2023 |
| 2023-12-18 | Eli Lilly and Company | $109 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIEN | 2023 | |
| 2023-12-15 | BeiGene AUS Pty Ltd | $2,727 | Research payment | Cash or cash equivalent | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell | 2023 | |
| 2023-12-15 | Insulet Corporation | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-12-15 | Genentech, Inc. | $346 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | 2023 |
| 2023-12-14 | Genmab U.S., Inc. | $85,513 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2023 |
| 2023-12-14 | ModernaTX, Inc. | $7,650 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | ABBVIE INC. | $5,110 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-14 | ModernaTX, Inc. | $4,980 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | ModernaTX, Inc. | $4,242 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | ModernaTX, Inc. | $3,915 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | ModernaTX, Inc. | $3,249 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | ModernaTX, Inc. | $2,879 | Research payment | Cash or cash equivalent | Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With | 2023 | |
| 2023-12-14 | Janssen Research & Development, LLC | $1,576 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-14 | ABBVIE INC. | $1,169 | Research payment | Cash or cash equivalent | A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants | 2023 | |
| 2023-12-14 | ABBVIE INC. | $490 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-14 | ABBVIE INC. | $445 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2023 | |
| 2023-12-13 | Travere Therapeutics, Inc. | $18,900 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-12-13 | E.R. Squibb & Sons, L.L.C. | $3,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Nivo in HL Pediatric (nivo+bv) - A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults | 2023 |
| 2023-12-13 | Travere Therapeutics, Inc. | $1,026 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-12-12 | PFIZER INC. | $13,150 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-12-12 | ModernaTX, Inc. | $59 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Su | 2023 | |
| 2023-12-11 | ABIOMED | $7,200 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Surpass | 2023 |
| 2023-12-11 | GENZYME CORPORATION | $5,937 | Research payment | Cash or cash equivalent | A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and S | 2023 | |
| 2023-12-11 | Janssen Research & Development, LLC | $5,400 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2023 |
| 2023-12-11 | Merck Sharp & Dohme LLC | $5,050 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2023 |
| 2023-12-11 | GENZYME CORPORATION | $2,403 | Research payment | Cash or cash equivalent | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2023 | |
| 2023-12-11 | Otsuka Pharmaceutical Co., Ltd. | $1,800 | Research payment | Cash or cash equivalent | A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT | 2023 | |
| 2023-12-11 | Otsuka Pharmaceutical Co., Ltd. | $600 | Research payment | Cash or cash equivalent | A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT | 2023 | |
| 2023-12-11 | Otsuka Pharmaceutical Co., Ltd. | $250 | Research payment | Cash or cash equivalent | A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $20,105 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $15,795 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $12,646 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $10,233 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | ABIOMED | $2,160 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | Use of the Impella ECP8482 in Patients Undergoing an Elective or Urgent High-Risk Percutaneous Coronary Intervention | 2023 |
| 2023-12-08 | TG Therapeutics, Inc. | $1,690 | Research payment | Cash or cash equivalent | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukem | 2023 | |
| 2023-12-08 | Incyte Corporation | $1,250 | Research payment | Cash or cash equivalent | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-T | 2023 | |
| 2023-12-08 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-T | 2023 | |
| 2023-12-08 | Incyte Corporation | $750 | Research payment | Cash or cash equivalent | A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-T | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $250 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | SANOFI US SERVICES INC. | $250 | Research payment | Cash or cash equivalent | A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinet | 2023 | |
| 2023-12-08 | ARRAY BIOPHARMA INC | $225 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER | 2023 |
| 2023-12-07 | Merck Sharp & Dohme LLC | $39,050 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a | 2023 |
| 2023-12-07 | Sumitomo Pharma America, Inc. | $15,286 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and wit | 2023 | |
| 2023-12-07 | PFIZER INC. | $1,826 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2023 |
| 2023-12-07 | Janssen Research & Development, LLC | $445 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-07 | ABBVIE INC. | $154 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menst | 2023 |
| 2023-12-06 | Daiichi Sankyo Inc. | $8,100 | Research payment | Cash or cash equivalent | DS3201-A-J101 | 2023 |
The latest 200 records of 1,835.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hackensack, NJ, county Bergen County, NJ, state New Jersey; placed by its city name.
| Measure | Place (city or town) Hackensack, NJ | County Bergen County, NJ | State New Jersey |
|---|---|---|---|
| Population B01003 | 46,057 | 962,316 | 9,343,809 |
| Population, 2020 census P1 | 46,030 | 955,732 | 9,288,994 |
| Median age B01002 | 41.8 | 42.0 | 40.1 |
| Under 18 B01001 | 14.7% | 20.9% | 21.8% |
| 65 and over B01001 | 18.1% | 18.2% | 17.2% |
| Households B11001 | 20,214 | 355,127 | 3,507,701 |
| Foreign born B05002 | 42.7% | 31.8% | 23.9% |
| Median household income B19013 | $84,277 | $124,884 | $103,556 |
| Median family income B19113 | $110,063 | $152,200 | $127,025 |
| Per capita income B19301 | $49,360 | $63,735 | $54,253 |
| Poverty rate B17001 | 12.1% | 6.8% | 9.7% |
| Unemployment rate B23025 | 7.7% | 5.8% | 6.3% |
| Civilian labor force B23025 | 27,398 | 527,974 | 5,003,179 |
| Mean commute (minutes) B08013 | 28.9 | 31.2 | 30.5 |
| Bachelor's degree or higher B15003 | 42.1% | 53.1% | 43.6% |
| Housing units B25001 | 21,361 | 369,613 | 3,791,354 |
| Owner-occupied B25003 | 36.6% | 65.3% | 63.8% |
| Renters B25003 | 63.4% | 34.7% | 36.2% |
| Median home value B25077 | $393,700 | $623,000 | $454,400 |
| Median gross rent B25064 | $1,911 | $1,914 | $1,720 |
| White, not Hispanic B03002 | 26.0% | 51.3% | 50.9% |
| Black B03002 | 18.1% | 5.4% | 12.2% |
| Hispanic or Latino B03002 | 37.2% | 22.7% | 22.5% |
| Asian B03002 | 13.8% | 16.8% | 10.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hackensack, NJ.
Comments